DOI 10.1016/j.ejca.2026.116742
Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.
Аннотация
INTRODUCTION
This study explores the associations between computed tomography (CT)-derived changes in body composition during the first three months of osimertinib monotherapy, systemic osimertinib exposure, and treatment outcomes in patients with advanced EGFR+ NSCLC.
MATERIALS AND
METHODS
Patients initiating osimertinib between January 2016 and January 2022 were selected from the START-TKI biomarker study. Osimertinib trough concentrations (Ctrough) were quantified. Body composition was assessed on baseline and three-month CT images using SliceOmatic. Loss of skeletal muscle index (SMI) was defined as a reduction of ≥ 1.3%. Associations between SMI loss and osimertinib Ctrough were estimated using linear mixed-effects modeling, while progression-free survival (PFS) and overall survival (OS) were evaluated using Cox proportional hazards models.
RESULTS
Fifty-three patients were included. Twenty-seven patients (56%) experienced SMI loss after three months. Median osimertinib Ctrough in the first three months was 212 ng/mL (IQR 159-279 ng/mL). Linear mixed-effects modeling indicated no association between SMI loss and osimertinib Ctrough over time (β = -17.3; 95% CI, -59.9-25.2; P = 0.42). Median follow-up was 53 months (95% CI, 46 - not reached). SMI loss was not associated with PFS (median PFS 11.5 vs. 11.8 months, HR: 0.99 [95% CI, 0.56-1.76]; P = 0.99). Patients in the highest-quartile Ctrough and those with EGFRexon21 L858R mutations had shorter PFS. SMI loss was an independent predictor of shorter OS (median OS 25.5 vs. 29.8 months, aHR: 2.04 [95% CI, 1.02-4.09]; P = 0.045) after adjusting for Ctrough and TP53 mutation status.
CONCLUSION
Early loss of SMI was not associated with osimertinib exposure, yet an independent predictor of shorter OS. Future research should explore whether nutritional interventions to preserve muscle mass improve osimertinib effectiveness.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.